Dianthus Therapeutics (NASDAQ:DNTH) Sees Strong Trading Volume

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) shares saw strong trading volume on Friday . 289,709 shares were traded during mid-day trading, an increase of 109% from the previous session’s volume of 138,307 shares.The stock last traded at $25.59 and had previously closed at $24.90.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Jefferies Financial Group increased their price target on Dianthus Therapeutics from $22.00 to $39.00 and gave the company a “buy” rating in a report on Friday, March 22nd. Wedbush increased their price target on Dianthus Therapeutics from $24.00 to $33.00 and gave the company an “outperform” rating in a report on Friday, March 22nd. Finally, Stifel Nicolaus assumed coverage on Dianthus Therapeutics in a research note on Thursday, February 15th. They set a “buy” rating and a $44.00 target price for the company. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $37.00.

Dianthus Therapeutics Stock Performance

The firm has a 50 day moving average price of $25.72 and a two-hundred day moving average price of $16.89.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings results on Thursday, March 21st. The company reported ($0.71) EPS for the quarter, topping analysts’ consensus estimates of ($1.11) by $0.40. The firm had revenue of $0.46 million during the quarter, compared to analyst estimates of $0.73 million. Sell-side analysts predict that Dianthus Therapeutics, Inc. will post -1.92 EPS for the current fiscal year.

Hedge Funds Weigh In On Dianthus Therapeutics

A number of hedge funds have recently bought and sold shares of DNTH. Tower Research Capital LLC TRC acquired a new position in Dianthus Therapeutics in the fourth quarter worth about $25,000. Citigroup Inc. bought a new position in Dianthus Therapeutics in the third quarter worth about $53,000. Dimensional Fund Advisors LP bought a new position in Dianthus Therapeutics in the fourth quarter worth about $153,000. Northern Trust Corp bought a new position in Dianthus Therapeutics in the fourth quarter worth about $159,000. Finally, Acadian Asset Management LLC bought a new position in Dianthus Therapeutics in the third quarter worth about $303,000. 47.53% of the stock is currently owned by institutional investors and hedge funds.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.